<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39358818</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1745-6215</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>02</Day></PubDate></JournalIssue><Title>Trials</Title><ISOAbbreviation>Trials</ISOAbbreviation></Journal><ArticleTitle>The impact of the COVID-19 pandemic and the changing landscape of CF on the cASPerCF trial: a real-world experience.</ArticleTitle><Pagination><StartPage>645</StartPage><MedlinePgn>645</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">645</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13063-024-08510-1</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chesshyre</LastName><ForeName>Emily L D</ForeName><Initials>ELD</Initials><AffiliationInfo><Affiliation>MRC Centre for Medical Mycology, University of Exeter, Exeter, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bradbury</LastName><ForeName>Jacob D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>MRC Centre for Medical Mycology, University of Exeter, Exeter, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cook</LastName><ForeName>Heather</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Clinical Trials Unit, University of Exeter, Exeter, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rocchi</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Ospedale Pediatrico Bambino Gesu, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roes</LastName><ForeName>Kit</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Women's Health Research, Liverpool Women's Hospital, Liverpool, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>, conect4children Stichting, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brüggemann</LastName><ForeName>Roger</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Warris</LastName><ForeName>Adilia</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-6586-3358</Identifier><AffiliationInfo><Affiliation>MRC Centre for Medical Mycology, University of Exeter, Exeter, UK. a.warris@exeter.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Great Ormond Street Hospital for Children, London, UK. a.warris@exeter.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trials</MedlineTA><NlmUniqueID>101263253</NlmUniqueID><ISSNLinking>1745-6215</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Authors EC and AW declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>23</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39358818</ArticleId><ArticleId IdType="pmc">PMC11446038</ArticleId><ArticleId IdType="doi">10.1186/s13063-024-08510-1</ArticleId><ArticleId IdType="pii">10.1186/s13063-024-08510-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Barry PJ, Mall MA, Alvarez A, Colombo C, de Winter-de Groot KM, Fajac IMK, et al. Triple therapy for cystic fibrosis Phe508del-gating and -residual function genotypes. N Engl J Med. 2021;385(9):815–25. 10.1056/nejmc2115966.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8982185</ArticleId><ArticleId IdType="pubmed">34437784</ArticleId></ArticleIdList></Reference><Reference><Citation>Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019;394(10212):1940–8. 10.1016/S0140-6736(19)32597-8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7571408</ArticleId><ArticleId IdType="pubmed">31679946</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutharsan S, Mckone EF, Downey DG, Duckers J, Macgregor G, Tullis E, et al. 24-week efficacy and safety of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR : a phase 3b randomised controlled trial. 10.1016/S2213-2600(21)00454-9</Citation><ArticleIdList><ArticleId IdType="pubmed">34942085</ArticleId></ArticleIdList></Reference><Reference><Citation>Middleton PG, Mall MA, Dřevínek P, Lands LC, McKone EF, Polineni D, et al. Elexacaftor–tezacaftor–ivacaftor for cystic fibrosis with a single Phe508del allele. N England J Med. 2019;381(19):1809–19. 10.1056/NEJMoa1908639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7282384</ArticleId><ArticleId IdType="pubmed">31697873</ArticleId></ArticleIdList></Reference><Reference><Citation>De Boeck K, Lee T, Amaral M, Drevinek P, Elborn JS, Fajac I, et al. Cystic fibrosis drug trial design in the era of CFTR modulators associated with substantial clinical benefit: stakeholders’ consensus view. J Cyst Fibros. 2020;19(5):688–95. 10.1016/j.jcf.2020.05.012.</Citation><ArticleIdList><ArticleId IdType="pubmed">32527602</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer-Hamblett N, van Koningsbruggen-Rietschel S, Nichols DP, VanDevanter DR, Davies JC, Lee T, et al. Building global development strategies for cf therapeutics during a transitional cftr modulator era. J Cyst Fibros. 2020;19(5):677–87. 10.1016/j.jcf.2020.05.011.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7492419</ArticleId><ArticleId IdType="pubmed">32522463</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell SC, Mall MA, Gutierrez H, Macek M, Madge S, Davies JC, et al. The lancet respiratory medicine commission on the future of care of cystic fibrosis. Lancet Respir Med. 2020;8(1):65. 10.1016/s2213-2600(19)30337-6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8862661</ArticleId><ArticleId IdType="pubmed">31570318</ArticleId></ArticleIdList></Reference><Reference><Citation>Heltshe SL, Cogen J, Ramos KJ, Goss CH. Cystic fibrosis: the dawn of a new therapeutic era. Am J Respir Crit Care Med. 2017;195(8):979–84. 10.1164/rccm.201606-1250PP.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5422649</ArticleId><ArticleId IdType="pubmed">27710011</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantha OL, Flamein F, Turner MA, Fernandes RM HRN of NNSGroup. Early impact of severe acute respiratory syndrome coronavirus 2 on pediatric clinical research: a pan-European and Canadian snapshot in time. J Pediatr. 2021;239:67-73.e3. 10.1016/j.jpeds.2021.08.028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8381618</ArticleId><ArticleId IdType="pubmed">34437911</ArticleId></ArticleIdList></Reference><Reference><Citation>McDermott MM, Newman AB. Preserving clinical trial integrity during the coronavirus pandemic. JAMA - J Am Med Assoc. 2020;323(21):2135–6. 10.1001/jama.2020.4689.</Citation><ArticleIdList><ArticleId IdType="pubmed">32211830</ArticleId></ArticleIdList></Reference><Reference><Citation>van Koningsbruggen-Rietschel S, Dunlevy F, Bulteel V, Downey DG, Dupont L. SARS-CoV-2 disrupts clinical research: the role of a rare disease-specific trial network. Eur Respir J. 2020;56(3):3–5. 10.1183/13993003.02114-2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7411273</ArticleId><ArticleId IdType="pubmed">32764115</ArticleId></ArticleIdList></Reference><Reference><Citation>Grantham-Hill S, Eyre M, Ramanan AV, Modi N, de Wildt SNLM. Global association of the COVID-19 pandemic with pediatric clinical trial publication. JAMA Netw Open. 2023;6(7): e2326313. 10.1001/jamanetworkopen.2023.26313.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10383004</ArticleId><ArticleId IdType="pubmed">37505501</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramanan AV, Modi N de WS c4c L from C 19 Group. Improving clinical paediatric research and learning from COVID-19: recommendations by the Conect4Children expert advice group. Pediatr Res. 2022;91(5):1069–77. 10.1038/s41390-021-01587-3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8184051</ArticleId><ArticleId IdType="pubmed">34099854</ArticleId></ArticleIdList></Reference><Reference><Citation>Vertex Pharmaceuticals. https://pi.vrtx.com/files/Canadapm_trikafta_en.pdf. 2021. Trikafta product monograph.</Citation></Reference><Reference><Citation>Horsley A. Lung clearance index in the assessment of airways disease. Respir Med. 2009;103(6):793–9. 10.1016/j.rmed.2009.01.025.</Citation><ArticleIdList><ArticleId IdType="pubmed">19246184</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw M, Khan U, Clancy JP, Donaldson SH, Sagel SD, Rowe SM, et al. Changes in LCI in F508del/F508del patients treated with lumacaftor/ivacaftor: results from the prospect study. J Cyst Fibros. 2020;19(6):931–3. 10.1016/j.jcf.2020.05.010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9125683</ArticleId><ArticleId IdType="pubmed">32513528</ArticleId></ArticleIdList></Reference><Reference><Citation>Rayment JH, Stanojevic S, Davis SD, Retsch-Bogart G, Ratjen F. Lung clearance index to monitor treatment response in pulmonary exacerbations in preschool children with cystic fibrosis. Thorax. 2018;73(5):451–8. 10.1136/thoraxjnl-2017-210979.</Citation><ArticleIdList><ArticleId IdType="pubmed">29449440</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrem L, Stanojevic S, Shaw M, Jensen R, McDonald N, Isaac SM, et al. Lung clearance index to track acute respiratory events in school-age children with cystic fibrosis. Am J Respir Crit Care Med. 2021;203(8):977–86. 10.1164/rccm.202006-2433oc.</Citation><ArticleIdList><ArticleId IdType="pubmed">33030967</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyilas S, Bauman G, Pusterla O, Ramsey K, Singer F, Stranzinger E, et al. Ventilation and perfusion assessed by functional MRI in children with CF: reproducibility in comparison to lung function. J Cyst Fibros. 2019;18(4):543–50. 10.1016/j.jcf.2018.10.003.</Citation><ArticleIdList><ArticleId IdType="pubmed">30348613</ArticleId></ArticleIdList></Reference><Reference><Citation>Stahl M, WielpüTz MO, Graeber SY, Joachim C, Sommerburg O, Kauczor HU, et al. Comparison of lung clearance index and magnetic resonance imaging for assessment of lung disease in children with cystic fibrosis. Am J Respir Crit Care Med. 2017;195(3):349–59. 10.1164/rccm.201604-0893oc.</Citation><ArticleIdList><ArticleId IdType="pubmed">27575911</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M, Hu XY, Desai S, Kwong E, Fu J, Flores E, et al. Factors influencing clinical trial participation for adult and pediatric patients with cystic fibrosis. J Cyst Fibros. 2021;20(1):57–60. 10.1016/j.jcf.2020.08.019.</Citation><ArticleIdList><ArticleId IdType="pubmed">32900673</ArticleId></ArticleIdList></Reference><Reference><Citation>Saiman L. Improving outcomes of infections in cystic fibrosis in the era of CFTR modulator therapy. Pediatr Pulmonol. 2019;54(S3):S18-26. 10.1002/ppul.24522.</Citation><ArticleIdList><ArticleId IdType="pubmed">31715086</ArticleId></ArticleIdList></Reference><Reference><Citation>VanDevanter DR, Mayer-Hamblett N. Innovating cystic fibrosis clinical trial designs in an era of successful standard of care therapies. Curr Opin Pulm Med. 2017;23(6):530–5. 10.1097/mcp.0000000000000418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5651982</ArticleId><ArticleId IdType="pubmed">28708817</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MA, Hildebrand H, Fernandes RM, de Wildt SN, Mahler F, Hankard R, et al. The conect4children (c4c) consortium: potential for improving European clinical research into medicines for children. Pharmaceut Med. 2021;35(2):71–9. 10.1007/s40290-020-00373-6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7979601</ArticleId><ArticleId IdType="pubmed">33539007</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>